Lts Lohmann Therapie-systeme Ag

Novaliq Gmbh

Ucb Pharma Gmbh

Sandra Wiedersberg

Michael Horstmann

Hans-Rainer Hoffmann

Gerd Hoffmann

Bernhard Günther

Dieter Scherer

Walter Müller

Peter Steinborn

Michael Hoffmann

Horst Dzekan

Elvira Kirstgen

Ralf-lngo Stein

Thomas Stumper

Dorothea Gutekunst

Thomas Stümper

Ralf-Ingo Stein

Viktoria Steinbrecher

The invention relates to the use of semi-fluorinated alkanes, in particular mixed with ethanol, as solubilising agents, permeation promoters and/or enhancers for lipophilic and/or poorly skin-permeable pharmaceutical agents that are administered via a transdermal therapeutic system (TTS), and to corresponding TTSs containing such substances.

Use of semi-fluorinated alkanes in transdermal therapeutic systems

The invention relates to a method for producing an active substance laminate, especially an oral active substance laminate (), having at least one active-substance-containing layer (), which is arranged on a substrate (), wherein the method comprises the following steps:

Method for producing an, in particular oral, active substance laminate, and active substance laminate, in particular oral active substance laminate

The invention relates to a transdermal therapeutic system (TTS) which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system incorporates a back layer and an active substance-containing layer that includes at least one peptide and a carrier substance.

Transdermal therapeutic system for the administration of peptides

The invention relates to a transdermal therapeutic system (TTS), which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system includes a back layer and an active substance-containing layer that contains at least one peptide and a carrier substance, preferably as a textile web material.

The invention relates to a transdermal therapeutic system (TTS) for administering pharmaceutical agents through the skin, comprising a back layer (R) impermeable to the agent and at least one layer (S) comprising the agent, wherein the layer (H) facing the skin comprises urea in solid form, allowing continuous administration of large quantities of agent over a long period of time.

Transdermal therapeutic system having urea components

Growing community of inventors

Steigra, Germany

Sandra Wiedersberg